RBC starts Becton Dickinson at Sector Perform, sees limited upside until 2027

RBC Capital Markets initiated coverage on Becton, Dickinson and Company (BD) with a Sector Perform rating and a $211 price target, anticipating growth acceleration primarily after 2026. This outlook follows BD's planned $17.5 billion spin-off and merger of its Biosciences and Diagnostics businesses with Waters Corp, which is expected to create a "New BD" focused on medical technology with synergy-driven value. However, RBC highlighted limited near-term earnings upside until fiscal 2027 due to initial FY2026 guidance of 3-3.5% organic growth and flat margins, despite potential for high single-digit earnings growth thereafter.

Analysis

RBC Capital Markets has initiated coverage on Becton, Dickinson and Company (BDX) with a 'Sector Perform' rating and a $211 price target, framing it as a long-term value creation story contingent on a major corporate restructuring. The core of this thesis is the planned $17.5 billion spin-off and merger of its Biosciences and Diagnostics businesses with Waters Corp (WAT), expected to close in Q1 2026. This transaction is designed to transform BDX into a pure-play medical technology leader with a significant consumables base, targeting markets with approximately 5% annual growth. RBC anticipates this 'New BD' can unlock substantial value through $345 million in synergies by the fifth year, a $4 billion cash distribution, and an increased focus on share buybacks and debt reduction. However, the analysis highlights a significant timing disconnect for investors; near-term performance is expected to be muted. The company's initial fiscal 2026 guidance points to modest 3% to 3.5% organic growth and flat margins, effectively capping earnings upside until fiscal 2027. The growth acceleration to a potential high single-digit earnings growth rate is a post-2027 event, projected to be fueled by $1 billion in annual R&D spending. With the stock trading at $180, RBC's price target implies a 17% upside, positioning the opportunity as one that requires investor patience.

Key Decisions for Investors

• Investors with a long-term horizon should consider the potential for value creation from the post-2026 'New BD' entity, which is expected to feature a more focused MedTech portfolio and enhanced capital returns.
• Be mindful of the near-term performance drag, as the company's own fiscal 2026 guidance of 3-3.5% organic growth and flat margins is likely to limit share price appreciation until the spin-merger is complete and synergies begin to materialize in fiscal 2027.
• Monitor key execution milestones, particularly the successful closure of the $17.5 billion transaction with Waters Corp in Q1 2026 and subsequent progress on achieving the targeted $345 million in synergies and deploying the $4 billion cash distribution.